AKT1 and neoplasm: The association of melatonin and rapamycin, an inhibitor of the Akt mammalian target of rapamycin (mTOR) signaling pathway, has a synergistic effect by reducing the toxicity of healthy cells and reducing the resistance of tumor cells against rapamycin [60].